CG Oncology (NASDAQ:CGON) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Unusually-high trading volume: About 1,772,084 shares traded mid-day (up 49% vs. the prior session); the stock last traded near $62.87, roughly flat/down 0.2% on the day.
• Analyst sentiment leans positive: Eleven Buys, two Holds and one Sell give a consensus rating of "Moderate Buy" with a consensus target of $69 and notable price targets ranging up to $93.
• Mixed fundamentals but strong institutional interest: CG Oncology reported Q results of ($0.51) EPS (beating estimates) on $2.32M revenue, has a negative PE (−30.29) and a $5.29B market cap, while major institutions (Vanguard, Wellington, Price T. Rowe, State Street) materially increased positions and institutional ownership stands at ~26.6%.

Shares of CG Oncology, Inc. (NASDAQ:CGON - Get Free Report) saw unusually-high trading volume on Wednesday . Approximately 1,772,084 shares were traded during mid-day trading, an increase of 49% from the previous session's volume of 1,188,735 shares.The stock last traded at $62.87 and had previously closed at $62.80.

Wall Street Analyst Weigh In

CGON has been the topic of several recent research reports. Weiss Ratings restated a "sell (d-)" rating on shares of CG Oncology in a research report on Wednesday, January 21st. HC Wainwright raised their target price on CG Oncology from $75.00 to $80.00 and gave the stock a "buy" rating in a research note on Friday, February 27th. Morgan Stanley set a $93.00 target price on CG Oncology in a report on Friday, January 9th. Wedbush assumed coverage on shares of CG Oncology in a report on Thursday, December 11th. They issued an "outperform" rating and a $70.00 price target on the stock. Finally, Royal Bank Of Canada boosted their price objective on shares of CG Oncology from $61.00 to $73.00 and gave the company an "outperform" rating in a research note on Wednesday, January 21st. Eleven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $69.00.

CG Oncology Stock Down 0.2%

The firm has a market capitalization of $5.29 billion, a PE ratio of -30.29 and a beta of 1.18. The firm's 50-day simple moving average is $53.32 and its 200-day simple moving average is $44.04.

CG Oncology (NASDAQ:CGON - Get Free Report) last issued its earnings results on Friday, February 27th. The company reported ($0.51) EPS for the quarter, topping the consensus estimate of ($0.61) by $0.10. The firm had revenue of $2.32 million during the quarter. On average, equities research analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Insider Activity

In other CG Oncology news, Director James Mulay sold 11,145 shares of the firm's stock in a transaction on Friday, January 9th. The stock was sold at an average price of $52.47, for a total transaction of $584,778.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CGON. Vanguard Group Inc. boosted its holdings in CG Oncology by 11.4% in the third quarter. Vanguard Group Inc. now owns 6,577,281 shares of the company's stock worth $264,933,000 after purchasing an additional 670,770 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of CG Oncology by 8.8% during the 4th quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company's stock valued at $249,111,000 after buying an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in shares of CG Oncology by 116.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company's stock worth $142,961,000 after buying an additional 1,854,386 shares during the last quarter. State Street Corp grew its holdings in shares of CG Oncology by 46.4% in the fourth quarter. State Street Corp now owns 2,996,695 shares of the company's stock worth $124,423,000 after acquiring an additional 950,028 shares during the period. Finally, Alliancebernstein L.P. grew its holdings in shares of CG Oncology by 15.0% in the second quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company's stock worth $56,270,000 after acquiring an additional 281,637 shares during the period. Institutional investors own 26.56% of the company's stock.

About CG Oncology

CG Oncology, Inc NASDAQ: CGON is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.